NCT02582801终止1 期
18F-Alfatide Ⅱ PET/CT in the Diagnosis and Treatment Response Evaluation of Breast Cancer Patients
Jiang Wu1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2015年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Maximum standardized uptake value (SUVmax)
研究概览
简要总结
18F-Alfatide Ⅱ PET/CT in breast cancer patients
详细描述
The investigators aim to assess the clinical application of 18F-Alfatide Ⅱ PET/CT in the diagnosis and treatment response monitoring of breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The patients have been suspected or diagnosed with breast cancer and they have not received any treatment; It must fulfill the ethical requirements and subjects have signed an informed consent.
排除标准
- •Pregnancy or nursing mothers; Those patients accompanied by other serious diseases such as cardiac functional insufficiency, hepatic and renal function insufficiency.
研究组 & 干预措施
breast cancer
Experimental
Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients
干预措施: 18F-Alfatide Ⅱ PET/CT (Drug)
benign breast lesions
Active Comparator
Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions
干预措施: 18F-Alfatide Ⅱ PET/CT (Drug)
结局指标
主要结局
Maximum standardized uptake value (SUVmax)
时间窗: 1 day
the uptake intensity of lesions
次要结局
未报告次要终点
研究者
Jiang Wu
Medical doctor
Jinling Hospital, China
研究点 (1)
Loading locations...
相似试验
招募中
不适用
18F-FDG PET/CT Imaging for Breast CancerBreast Cancer FemaleBreast Cancer RecurrentNCT05730608Vestre Viken Hospital Trust300
已完成
不适用
The Role of 68GA DOTATATE PET/CT In Breast Cancer ImagingBreast CancerNCT06359054Celal Bayar University16
已完成
不适用
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of MalignancyNeoplasmsNCT00725387Stanford University214
进行中（未招募）
2 期
18F-fluoroestradiol (FES) PET/CT for Breast CancerBreast CancerNCT04883814Hoag Memorial Hospital Presbyterian124
已完成
不适用
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast CancerEstrogen Receptor PositiveHER2/Neu NegativeMale Breast CarcinomaStage IA Breast CancerStage IB Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerNCT01928186University of Washington28